Inventiva SA represents values of innovation, research, and commitment to improving patients' lives. With a strong corporate philosophy, the company focuses on developing breakthrough therapies for the treatment of fibrotic diseases, oncology, and NASH. Inventiva SA's dedication to scientific excellence and collaborative partnerships drives its mission to address unmet medical needs and provide effective therapeutic solutions. Through its innovative approach and commitment to patient health, Inventiva SA has positioned itself as a leading player in the pharmaceutical industry.

Inventiva SA is primarily present in France and Switzerland.

Inventiva SA, a leading company in the stock market, has accomplished several significant milestones. One of its notable achievements includes the successful completion of Phase 2b clinical trials for its drug candidate, lanifibranor. Additionally, Inventiva SA has successfully secured partnerships and collaborations with various pharmaceutical companies to further advance its innovative research and development. The company's commitment to building a strong and diverse portfolio has also resulted in obtaining key patents and regulatory approvals for its ground-breaking therapies. These remarkable achievements highlight Inventiva SA's dedication to revolutionizing the healthcare industry and position the company as a promising investment opportunity.

Inventiva SA is a pharmaceutical company founded in 2011 in France. The company specializes in the development and commercialization of innovative therapies for the treatment of diseases with high unmet medical needs. With a strong expertise in drug discovery and medicinal chemistry, Inventiva aims to address significant therapeutic challenges through its proprietary technology platforms. The company has a diverse portfolio of drug candidates targeting a range of conditions, including fibrosis, oncology, and rare genetic diseases. Inventiva has established collaborations with various research and academic institutions to support its research efforts. With a dedicated team and promising pipeline, Inventiva SA is poised to make a significant contribution to the healthcare industry.

The main competitors of Inventiva SA in the market include other companies operating in the biopharmaceutical industry, such as Novartis, Amgen, Gilead Sciences, and Pfizer. These companies also focus on research, development, and commercialization of innovative therapies for various diseases.

Inventiva SA is primarily active in the biopharmaceutical industry.

The business model of Inventiva SA focuses on the development and commercialization of innovative therapies for the treatment of various diseases. As a biopharmaceutical company, Inventiva SA aims to discover and develop small molecule drugs that target various nuclear receptors involved in the regulation of gene expression. By leveraging its expertise in nuclear receptors, Inventiva SA aims to bring novel therapies to market that can address unmet medical needs. With a strong pipeline of drug candidates in various stages of development, Inventiva SA is dedicated to improving patients' lives and creating value for its shareholders through the research and development of innovative therapies.

Inventiva KGV ir -0,70.

Inventiva KUV ir 32,87.

AlleAktien kvalitātes vērtējums Inventiva ir 7/10.

gaidāmā Inventiva apgrozījums ir 2,59 milj. EUR.

gaidāmā Inventiva peļņa ir -121,53 milj. EUR.

The company Inventiva SA is a company specializing in the development of therapies for serious diseases. The company is based in France and also has branches in Germany and the USA. The various divisions of Inventiva SA include drug development and clinical research, as well as the manufacturing of diagnostics and medications. The company specializes in the development of medications for serious diseases such as rare genetic disorders or fibrosis. It takes an interdisciplinary approach and works closely with research institutions and biopharmaceutical companies. One of Inventiva SA's key products is the medication Lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a liver disease caused by obesity and diabetes, which can lead to cirrhosis and liver cancer. Lanifibranor is intended to improve liver health and reduce inflammation by influencing various signaling pathways in the body. The medication is currently in clinical development and has already shown promising results in clinical trials. Another product of Inventiva SA is the diagnostic test called Odiparcil, which supports the treatment of mucopolysaccharidosis (MPS). MPS is a rare genetic disease that can cause debilitating symptoms such as bone pain, shortness of breath, and changes in facial features. The Odiparcil test allows for the diagnosis of MPS and helps doctors choose the right therapy for their patients. Inventiva SA mainly finances its research and development projects through partnerships and licensing agreements with major pharmaceutical companies. For example, the company has a partnership with AbbVie, a global leader in biopharmaceuticals, to advance the development of Lanifibranor. Additionally, the company has significant investments from public and private investors as well as foundations. Overall, Inventiva SA takes a strategic and scientific approach to develop medications and diagnostics for serious diseases with unmet medical needs. The company has a strong pipeline of products in development and a promising partnership with a global biopharmaceutical manufacturer. With its focus on developing innovative therapies for complex diseases, Inventiva SA can contribute to improving the lives of millions of patients worldwide.

Inventiva izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Inventiva vai uzņēmums nedod dividendes.

Inventiva ISIN ir FR0013233012.

Inventiva WKN ir A2DLV9.

Inventiva simbols ir IVA.PA.

Pēdējo 12 mēnešu laikā Inventiva maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Inventiva plāno maksāt dividendes 0 EUR apmērā.

Inventiva pašreizējā dividendu rentabilitāte ir .

Inventiva maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Inventiva pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Inventiva tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Inventiva apmērā 0 EUR, kas tika izmaksāta 26.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.09.2024..

Pēdējās dividendes izmaksa notika 26.09.2024..

Gadā 2023, Inventiva izmaksāja 0 EUR dividendes.

Inventiva dividendes tiek izmaksātas EUR.